Crossmark

Transferrin modified PEG–PLGA nanoparticles: highly effective notoginsenoside R1 formulations for the treatment of ulcerative colitis

Published Online: 2024-01-04

Published Print: 2024-05

Authors

Zhou, Limei

Shang, Yunxia

Wang, Yaru

Wei, Xiaohui https://orcid.org/0000-0001-9105-5186
Funding

Funding for this research was provided by:

Shanghai Municipal Education Commission (2020LK012)
License Information

Text and Data Mining valid from 2024-01-04

Version of Record valid from 2024-01-04
More Information

Article History

Received: 19 September 2023

Accepted: 17 December 2023

First Online: 4 January 2024

Declarations

:

: All authors (Limei Zhou, Yunxia Shang, Yaru Wang and Xiaohui Wei) declare that they have no conflict of interest.

: Animal experiments were carried out following the Institutional Animal Care guidelines and approved by the Animal Experimental Ethical Committee of Shanghai University of Traditional Chinese Medicine (Shanghai, China) (certification number: PZSHUTCM200731011).

Document is current